[Clinical analysis of dopa-responsive dystonia and mutation analysis of the GCH I gene]

Zhonghua Er Ke Za Zhi. 2006 Jul;44(7):492-5.
[Article in Chinese]

Abstract

Objective: To investigate the clinical characteristics and GCH I gene mutations in patients with dopa-responsive dystonia (DRD).

Methods: The clinical features of 3 families with 6 affected members and 8 sporadic cases were analyzed to determine the clinical characteristics, and 2 families with 4 affected members and 2 sporadic cases were screened for mutations of the GCH I gene.

Results: Age at onset was (10 +/- 3) years. Onset occurred earlier in female (9 +/- 4) years than in male (12 +/- 1) years. The initial symptom was a gait disorder, dystonia or tremor in most patients and nine patients (64%) presented with diurnal fluctuation. Thirteen patients (93%) were cured and one was improved after administration of low doses of levodopa for 3 months and no long-term side effects of levodopa had occurred. Two independent mutations were found in three patients. Gln161Pro, a new missense mutation, was found in a sporadic case, leading to a relatively severe phenotype. The two patients with mild phenotype in one family were found to have Lys224Arg mutation, as previously described.

Conclusions: DRD patients have diverse phenotypes and diurnal fluctuation is an important feature. They have dramatic and sustained response to levodopa. There may be a correlation between genotype and phenotype. The detection of GCH I mutations is helpful in early diagnosis of non-typical cases.

Publication types

  • English Abstract

MeSH terms

  • Age of Onset
  • Child
  • China
  • DNA Mutational Analysis
  • Dopamine Agents / therapeutic use*
  • Dystonia / diagnosis
  • Dystonia / drug therapy
  • Dystonia / genetics*
  • Dystonia / physiopathology*
  • Early Diagnosis
  • Female
  • GTP Cyclohydrolase / genetics*
  • Genotype
  • Humans
  • Levodopa / therapeutic use*
  • Male
  • Molecular Sequence Data
  • Mutation*
  • Mutation, Missense
  • Pedigree
  • Phenotype
  • Polymerase Chain Reaction
  • Sex Factors
  • Treatment Outcome

Substances

  • Dopamine Agents
  • Levodopa
  • GTP Cyclohydrolase